glp 1 comparison chart New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks 1 microdosing with Fitish RX Excellent head-to-head comparison of current

BMJ , 2026

The estimated mean difference was 0.31% (95% bootstrap CI 1.46% to 0.91%), indicating substantial variability in glycemic response

Roche Johnson & Johnson Zealand Pharma Hanmi Pharmaceutical Rhythm Pharmaceuticals Structure Therapeutics Viking Therapeutics Altimmune Roche Diabetes Care Biocon Genfit Regeneron Pharmaceuticals Novo Nordisk Headquarters: Bagsvrd, Denmark Novo Nordisk is a global pharmaceutical company, kind of a leading player in diabetes and obesity care

104 Cotadutide by AstraZeneca and efinopegdutide by Merck Sharp & Dohme are other GLP-1R/GCGR dual agonists

Dr Simon Cork of Anglia Ruskin University said competition in the form of new medications will also play a big role in any future pricing arrangements of those that now exist